Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes (original) (raw)
- Original Manuscript
- Published: 09 September 1999
- R Suzuki1,
- K Uehira3,
- Y Yatabe4,
- Y Kagami3,
- M Ogura3,
- H Suzuki5,
- A Oyama6,
- Y Kodera7,
- R Ueda2,
- Y Morishima3,
- S Nakamura4 &
- …
- M Seto1
Leukemia volume 13, pages 1441–1447 (1999)Cite this article
- 488 Accesses
- 108 Citations
- 1 Altmetric
- Metrics details
Abstract
Diffuse large B cell lymphoma (DLBL) constitutes the greatest percentage of adult non-Hodgkin’s lymphomas and represents a diverse spectrum of lymphoid neoplasms. Clinicopathologic, phenotypic and genotypic findings were correlated and compared for 63 DLBL cases to investigate whether they represent clinically relevant subtypes. They were all cyclin D1 negative and were phenotypically divided into three groups, ie group I (CD5+ type, n = 11), group II (CD5− CD10+ type, n = 19), and group III (CD5− CD10− type, n = 33). Data were correlated by observing the respective gene rearrangement and expression of BCL2 and BCL6. In clinical aspects, the group I cases demonstrated a significantly inferior survival than those of the other two groups (log-rank test, P = 0.016). Although rearrangement of BCL2 and BCL6 did not show any inclination to a specific subgroup, the immunohistochemical detection of BCL2 was less frequent, at a statistically significant level (P = 0.011), in group II (50%) than in group I (82%) and III (82%) cases. This appears to confirm the unique aspect of the CD5− CD10+ type DLBL, indicating a certain relationship with the normal germinal center cells which usually lack BCL2 expression. The BCL6 protein expression was detected in most of the present DLBL cases (92%) irrespective of this grouping. These data suggest that the phenotypic delineation by the detection of CD5 and CD10 will improve our understanding of DLBL and be helpful in a future subgrouping of DLBL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Authors and Affiliations
- Laboratory of Chemotherapy, Aichi Cancer Center Research Institute, Japan
S Harada, R Suzuki & M Seto - Second Department of Internal Medicine, Nagoya City University School of Medicine, Japan
S Harada & R Ueda - Department of Hematology and Chemotherapy, Aichi Cancer Center Hospital, Japan
K Uehira, Y Kagami, M Ogura & Y Morishima - Department of Pathology and Clinical Laboratories, Aichi Cancer Center Hospital, Japan
Y Yatabe & S Nakamura - Department of Internal Medicine, Okazaki Municipal Hospital, Japan
H Suzuki - Department of Internal Medicine, Aichi Prefectural Hospital, Japan
A Oyama - Department of Internal Medicine, Japanese Red Cross, Nagoya First Hospital, Japan
Y Kodera
Authors
- S Harada
- R Suzuki
- K Uehira
- Y Yatabe
- Y Kagami
- M Ogura
- H Suzuki
- A Oyama
- Y Kodera
- R Ueda
- Y Morishima
- S Nakamura
- M Seto
Rights and permissions
About this article
Cite this article
Harada, S., Suzuki, R., Uehira, K. et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes.Leukemia 13, 1441–1447 (1999). https://doi.org/10.1038/sj.leu.2401487
- Received: 08 March 1999
- Accepted: 11 May 1999
- Published: 09 September 1999
- Issue Date: 01 September 1999
- DOI: https://doi.org/10.1038/sj.leu.2401487